has a place in the effort to avert acute attacks; however, its use is restricted within the allergic asthma subtype. The treatment of an already established exacerbation is more straight forward ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

The following is a summary of “Clinical remission attainment, definitions, and correlates among patients with severe asthma ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca ... Airsupra was found to significant reduce the risk of severe exacerbations compared to albuterol in patients with ...

Arterial-Blood Studies during Treatment of Severe Refractory Bronchial Asthma in Case 2 on May 17, after Theophylline and Epinephrine (1), at 8:00 A.M., when the Asthma Was Refractory to ...

While the exact cause of asthma is unknown, certain genetic factors can increase the risk of developing the disease.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

Human Metapneumovirus HMPV is a respiratory virus that can cause cold-like symptoms to severe infections like pneumonia Learn ...

A recent study published in The Journal of Allergy and Clinical Immunology: In Practice found that gestational diabetes ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...